Nebenwirkungen · Abilify Maintena
Abilify Maintena 720 mg prolonged-release suspension for injection in pre-filled syringe Abilify Maintena 960 mg prolonged-release suspension for injection in pre-filled syringe · Abschnitt 4.8 · PDF-Seite 31
HOS-129456 · Präparat HOS-096717
The most frequently observed ADRs reported in ≥ 5 % of patients in two double-blind, long-term trial of Abilify Maintena 400 mg/300 mg were weight increased (9.0%), akathisia (7.9%) and insomnia (5.8%). In the Abilify Maintena 960 mg/720 mg clinical trials, weight increased (22.7%), injection site pain (18.2%) akathisia (9.8 %), anxiety (8.3 %), headache (7.6 %), insomnia (7.6 %), and constipation (6.1 %) were the most frequently observed ADRs.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-10-28T15:16:00Z · SHA-256 41ea025269b746fee63511b9edbf4ea222d53988b45b27fd317f27f82cafb4fe · Passage 899e941342ddbfbdf673d911983c8fade63d694b9c06d5258bd63030316d6b73 · Zeichen 450–898 im Abschnitt